AM-11245

AM-11245 is a chemical compound that belongs to the class of organic compounds known as benzazepines. Benzazepines are compounds containing a benzene ring fused to an azepine ring (a seven membered aliphatic ring with one nitrogen atom replacing a carbon atom). AM-11245 is specifically an analgesic drug that was developed by AstraZeneca.

History

AM-11245 was first synthesized and studied by AstraZeneca, a British-Swedish multinational pharmaceutical and biopharmaceutical company. The development of AM-11245 was part of AstraZeneca's broader research into analgesic drugs, which are used to relieve pain.

Chemical Structure

The chemical structure of AM-11245 is characterized by a benzazepine core, which is a common structural component in a variety of therapeutic agents. This core is a seven-membered heterocyclic ring with one nitrogen atom. The benzazepine core of AM-11245 is substituted with various functional groups, which contribute to its analgesic properties.

Pharmacology

As an analgesic, AM-11245 works by interacting with the body's pain pathways. While the exact mechanism of action is not fully understood, it is believed that AM-11245 may interact with opioid receptors in the brain and spinal cord, which are involved in the perception of pain.

Clinical Use

The clinical use of AM-11245 is primarily focused on the management of pain. However, like all drugs, AM-11245 is associated with potential side effects and risks, and its use must be carefully managed by a healthcare professional.

See Also

• AstraZeneca
• Analgesic
• Benzazepines
• Opioid receptors

‎

‎